REVTx-99

• REVTx-99 is a nasal solution for the prevention and/or treatment of respiratory viral infection and chronic nasal congestion.

• Sixty seven percent (67%) of subjects in our Phase 1 healthy volunteer study showed a greater than 5-fold increase in IP-10. Three-fold changes in IP-10 have been shown to be protective against influenza and rhinovirus infection in other clinical studies. Additional information can be found in our corporate presentation. 

Background REVTx-99a Phase 1 Study Safety and Biomarker Results REVTx-99b Phase 2 Viral Challenge Study

REVTx-99b Phase 1 Allergen Challenge Study

REVTx-99b Phase 1 Allergen Challenge Study

Revelation is conducting a Phase 1 allergen challenge study of REVTx-99b. This study will evaluate the potential of REVTx-99b to prevent or treat allergies brought on by ragweed pollen. Success in this study will support later stage studies required for approval. An outline of the study design and objectives can be found in the corporate presentation.